News

Autologous fat grafting may be able to treat alopecia by controlling inflammation, enhancing symptoms, and boosting hair density.

A recent study confirmed that collagen peptides effectively counteract age-related skin issues such as reduced density and increased dryness.

Researchers identified mistrust, social stigma, and language barriers as major obstacles for ethnic minorities in skin research.

After treatment with the topical JAK inhibitor, researchers reported significant improvement of lesional skin.

In a review, researchers reported that ethnicity plays a role in outcomes, presentations, and more for individuals with systemic sclerosis.

Anthony Nuara, MD, PhD, reviewed a case study of a 32-year-old professional makeup artist who was concerned about her depigmented patches affecting her livelihood.

The National Psoriasis Foundation's new report provides an overview of the health impacts of psoriasis, revealing significant issues in care and outcomes.

This week’s collection of the latest dermatologic studies includes the prevalence of vulvar dermatoses among ethnically diverse patients, the adaptation of the Mackie melanoma risk stratification tool into a tablet-based patient questionnaire, siblings diagnosed with hereditary sensory and autonomic neuropathy, and more.

The study found 95.8% of ocular AEs occurred in AD patients, while SA patients reported only 4.2% of these events.

Over 6 weeks, most saw patients saw improvement, with daily medication linked to better quality of life and reduced skin picking.

Researchers say promising study findings warrant further exploration of EID's potential on a larger scale.

A review found repeated laser treatments show cumulative benefits, including improved collagen density and skin elasticity over time.

At the correct dosage, researchers noted non-significant changes in BMI or metabolic syndrome markers among patients.

The availability is notable as it introduces the first oral treatment option for young psoriasis patients.

Latanya Benjamin, MD, FAAD, reviewed a case study of a 35-year-old woman with a 10-year history of vitiligo and concomitant atopic dermatitis

Patients with AD and psoriasis both report diminished levels of happiness compared to the general population.

David Goldberg, MD, JD, stated the use of drugs and devices for conditions that are not otherwise indicated is widespread among physicians and is generally not considered experimental or investigational.

Researchers assessed patterns of referral from a primary dermatological clinic in Japan.

Preliminary data suggests that the exosomes could effectively address common skin concerns, including firmness, photodamage, and fine lines.

Researchers stated the integration of wearable sensors with AI could potentially revolutionize care for patients with atopic dermatitis.

Qing Yu Christina Weng, MD, shares insights into the drug's advancement following preliminary phase 1 findings.

David Mandell, JD, MBA, stated in the quest to protect against malpractice liability, insurance is certainly the first and most important line of defense.

Health care professionals are recognizing the growing need for advanced technology in modern medical practice.

Keep up with the latest headlines in dermatology from the past week, including honoring the teenage inventor of a soap to treat skin cancer, the US FDA's approval of nemolizumab for prurigo nodularis, and more.

In case you missed it, this week we had news about the FDA approval of nemolizumab for prurigo nodularis, insights from AbbVie's Science of Skin event, new phase 3 data of izokibep for hidradenitis suppurativa, and more.

Explore recent research in in vitro complex skin models to study skin homeostasis, aging, and skin disease.

The study found that higher doses of BTX “significantly” improved facial erythema and patient quality of life compared to lower doses.

Mendelian randomization suggested a potential causal relationship between the 2 variables.

The use of microneedling, however, resulted in decreases in pigmentation and pruritus.

“This approval reflects our dedication to ensuring high-quality treatments are universally accessible,” Claire D’Abreu-Hayling, chief scientific officer of Sandoz, said in a news release.